ArticleBiomaterials research2026
A Tumor-Responsive Enzymatic Cascade System Inducing pH-Activable Metabolic Starvation and H
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional tumor-targeted therapies primarily focus on drug delivery systems exploiting the tumor microenvironment for controlled drug release. While prodrug strategies activate small-molecule drugs in tumors, they rely on single-step chemical conversions and lack sustained tumor-selective activity. Here, a novel strategy of tumor-responsive, enzymatic cascade therapy is introduced by co-delivering arginine decarboxylase (RDC) and diamine oxidase (DAO) into the tumor site. Unlike traditional arginine depletion strategies, RDC remains inactive at physiological pH and is selectively activated under acidic tumor conditions, ensuring localized metabolic starvation while minimizing systemic toxicity. To overcome a key limitation of RDC-namely, the accumulation of toxic agmatine-RDC is co-delivered with DAO using a chitosan-functionalized Pluronic-based nanocarrier (RDC/DAO@NC), enabling tumor-specific conversion of agmatine into hydrogen peroxide (H
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.